Table 3 Characteristics of studies on the role of pre-treatment NLR on NSCLC patients treated with SBRT
Author | Year | Region | # pts | Median OS (months) | 3- year OS (%) | Median NLR (range) | NLR cutoff | OS | Tumor recurrence | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High NLR | Low NLR | HR (95% CI) | P value | HR (95% CI) | P value | Type | |||||||
Current | 2022 | USA | 286 | 23.48 | 40.1 | 57.1 | 3.06 (2.21–4.33) | 3.28 | 1.06 (1.02–1.10) | 0.005a | 1.08 (0.97–1.21) | 0.16 | nodal |
1.11(1.05–1.18) | < 0.001a | distant | |||||||||||
AduQuaye | 2022 | Canada | 61 | 36 | NR | NR | 3.42 (0.27–13.69) | NR | 1.26 (1.04–1.53) | 0.017a | 1.05(1–1.1) | 0.021a | local |
Kotha | 2021 | USA | 389 | 31.5 | NR | NR | 3.0 (0.4–42) | 4 | 1.44 (1.12–1.86) | 0.01a | NR | NR | NR |
Sebastian | 2019 | USA | 156 | 32.9 | NR | NR | 3.6 (0.2–41.8) | 3.6 | 1.91 (1.09–3.33) | 0.023a | 1.21 (0.42–3.49) | 0.73 | local |
1.30 (0.61–2.74) | 0.5 | regional nodal | |||||||||||
1.95 (0.81–4.72) | 0.14 | distant | |||||||||||
Luo | 2018 | China | 63 | NR | NR | NR | 2.47 (0.86–7.29) | 2.06 | 1.489 (1.096–2.021)b | 0.011b | NR | NR | NR |
Shaverdian | 2016 | USA | 118 | NR | 61.0 | 92.0 | 2.79(0.95–11.6) | 2.18 | 1.477 (NR) | 0.008a | 0.816 (NR) | 0.456 | locoregional |
1.255 (NR) | 0.438 | distant | |||||||||||
Giuliani | 2016 | Canada | 122 | 43.7 | 41.2 | 66.2 | 3.0 (0.3–22.0) | 3 | 1.22 (1.08–1.38) | 0.001a | NR | NR | NR |
Cannon | 2015 | USA | 59 | 43 | NR | NR | 2.8 (0.5–33.0) | 2.98 | NR | 0.005a | NR | 0.937 | nonlocal |